Prognostic value of regulatory T cells, lymphomaassociated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: A southwest oncology group study

J. W. Sweetenham, B. Goldman, M. L. LeBlanc, J. R. Cook, R. R. Tubbs, O. W. Press, D. G. Maloney, R. I. Fisher, L. M. Rimsza, Rita Braziel, E. D. Hsi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy. Patients and methods: Tissue microarrays were constructed from archived tissue obtained from patients on three sequential Southwest Oncology Group (SWOG) trials for FL. All three trials included anthracycline-based chemotherapy. Anti-CD20 monoclonal antibodies were included for patients in the latter two trials. Immunohistochemistry was used to study the number and distribution of cells staining for forkhead box protein P3 (FOXP3) and lymphoma-associated macrophages (LAMs) and the number of lymphoma cells staining for myelomaassociated antigen-1 (MUM-1). Cox proportional hazards regression was used to evaluate the association between marker expression and overall survival (OS). Results: The number or pattern of infiltrating FOXP3 cells and LAMs did not correlate with OS in sequential SWOG studies for FL. The presence of MUM-1 correlated with lower OS for patients who received monoclonal antibody but not for those treated with chemotherapy alone. Conclusions: Immune cell composition of lymph nodes did not correlate with OS in this analysis of trials in FL. The mechanism of the observed correlation between MUM-1 expression and adverse prognosis in patients receiving monoclonal antibody therapy requires confirmation.

Original languageEnglish (US)
Pages (from-to)1196-1202
Number of pages7
JournalAnnals of Oncology
Volume21
Issue number6
DOIs
StatePublished - Oct 29 2009

Fingerprint

Follicular Lymphoma
Regulatory T-Lymphocytes
Macrophages
Monoclonal Antibodies
Lymphoma
Survival
Therapeutics
Cell Count
Staining and Labeling
Forkhead Transcription Factors
Cellular Microenvironment
Drug Therapy
Anthracyclines
Survival Analysis
Lymph Nodes
Immunohistochemistry
Antigens
Neoplasms

Keywords

  • Follicular lymphoma
  • LAMs
  • MUM-1
  • Prognosis
  • T<inf>regs</inf>

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Prognostic value of regulatory T cells, lymphomaassociated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy : A southwest oncology group study. / Sweetenham, J. W.; Goldman, B.; LeBlanc, M. L.; Cook, J. R.; Tubbs, R. R.; Press, O. W.; Maloney, D. G.; Fisher, R. I.; Rimsza, L. M.; Braziel, Rita; Hsi, E. D.

In: Annals of Oncology, Vol. 21, No. 6, 29.10.2009, p. 1196-1202.

Research output: Contribution to journalArticle

Sweetenham, J. W. ; Goldman, B. ; LeBlanc, M. L. ; Cook, J. R. ; Tubbs, R. R. ; Press, O. W. ; Maloney, D. G. ; Fisher, R. I. ; Rimsza, L. M. ; Braziel, Rita ; Hsi, E. D. / Prognostic value of regulatory T cells, lymphomaassociated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy : A southwest oncology group study. In: Annals of Oncology. 2009 ; Vol. 21, No. 6. pp. 1196-1202.
@article{903b23ca667e4a0bb8e1e461fbae725c,
title = "Prognostic value of regulatory T cells, lymphomaassociated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: A southwest oncology group study",
abstract = "Background: The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy. Patients and methods: Tissue microarrays were constructed from archived tissue obtained from patients on three sequential Southwest Oncology Group (SWOG) trials for FL. All three trials included anthracycline-based chemotherapy. Anti-CD20 monoclonal antibodies were included for patients in the latter two trials. Immunohistochemistry was used to study the number and distribution of cells staining for forkhead box protein P3 (FOXP3) and lymphoma-associated macrophages (LAMs) and the number of lymphoma cells staining for myelomaassociated antigen-1 (MUM-1). Cox proportional hazards regression was used to evaluate the association between marker expression and overall survival (OS). Results: The number or pattern of infiltrating FOXP3 cells and LAMs did not correlate with OS in sequential SWOG studies for FL. The presence of MUM-1 correlated with lower OS for patients who received monoclonal antibody but not for those treated with chemotherapy alone. Conclusions: Immune cell composition of lymph nodes did not correlate with OS in this analysis of trials in FL. The mechanism of the observed correlation between MUM-1 expression and adverse prognosis in patients receiving monoclonal antibody therapy requires confirmation.",
keywords = "Follicular lymphoma, LAMs, MUM-1, Prognosis, T<inf>regs</inf>",
author = "Sweetenham, {J. W.} and B. Goldman and LeBlanc, {M. L.} and Cook, {J. R.} and Tubbs, {R. R.} and Press, {O. W.} and Maloney, {D. G.} and Fisher, {R. I.} and Rimsza, {L. M.} and Rita Braziel and Hsi, {E. D.}",
year = "2009",
month = "10",
day = "29",
doi = "10.1093/annonc/mdp460",
language = "English (US)",
volume = "21",
pages = "1196--1202",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Prognostic value of regulatory T cells, lymphomaassociated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy

T2 - A southwest oncology group study

AU - Sweetenham, J. W.

AU - Goldman, B.

AU - LeBlanc, M. L.

AU - Cook, J. R.

AU - Tubbs, R. R.

AU - Press, O. W.

AU - Maloney, D. G.

AU - Fisher, R. I.

AU - Rimsza, L. M.

AU - Braziel, Rita

AU - Hsi, E. D.

PY - 2009/10/29

Y1 - 2009/10/29

N2 - Background: The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy. Patients and methods: Tissue microarrays were constructed from archived tissue obtained from patients on three sequential Southwest Oncology Group (SWOG) trials for FL. All three trials included anthracycline-based chemotherapy. Anti-CD20 monoclonal antibodies were included for patients in the latter two trials. Immunohistochemistry was used to study the number and distribution of cells staining for forkhead box protein P3 (FOXP3) and lymphoma-associated macrophages (LAMs) and the number of lymphoma cells staining for myelomaassociated antigen-1 (MUM-1). Cox proportional hazards regression was used to evaluate the association between marker expression and overall survival (OS). Results: The number or pattern of infiltrating FOXP3 cells and LAMs did not correlate with OS in sequential SWOG studies for FL. The presence of MUM-1 correlated with lower OS for patients who received monoclonal antibody but not for those treated with chemotherapy alone. Conclusions: Immune cell composition of lymph nodes did not correlate with OS in this analysis of trials in FL. The mechanism of the observed correlation between MUM-1 expression and adverse prognosis in patients receiving monoclonal antibody therapy requires confirmation.

AB - Background: The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy. Patients and methods: Tissue microarrays were constructed from archived tissue obtained from patients on three sequential Southwest Oncology Group (SWOG) trials for FL. All three trials included anthracycline-based chemotherapy. Anti-CD20 monoclonal antibodies were included for patients in the latter two trials. Immunohistochemistry was used to study the number and distribution of cells staining for forkhead box protein P3 (FOXP3) and lymphoma-associated macrophages (LAMs) and the number of lymphoma cells staining for myelomaassociated antigen-1 (MUM-1). Cox proportional hazards regression was used to evaluate the association between marker expression and overall survival (OS). Results: The number or pattern of infiltrating FOXP3 cells and LAMs did not correlate with OS in sequential SWOG studies for FL. The presence of MUM-1 correlated with lower OS for patients who received monoclonal antibody but not for those treated with chemotherapy alone. Conclusions: Immune cell composition of lymph nodes did not correlate with OS in this analysis of trials in FL. The mechanism of the observed correlation between MUM-1 expression and adverse prognosis in patients receiving monoclonal antibody therapy requires confirmation.

KW - Follicular lymphoma

KW - LAMs

KW - MUM-1

KW - Prognosis

KW - T<inf>regs</inf>

UR - http://www.scopus.com/inward/record.url?scp=77953966767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953966767&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp460

DO - 10.1093/annonc/mdp460

M3 - Article

C2 - 19875761

AN - SCOPUS:77953966767

VL - 21

SP - 1196

EP - 1202

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -